AVOID PUTTING YOUR NEXT DEAL AT RISK
Now is the time to revisit your IP due diligence review protocol to ensure your company possesses the necessary tools to conduct a thorough, comprehensive and accurate review.
Within the life sciences industries, IP is THE driving force behind a deal. Whether negotiating a merger, collaboration or licensing agreement, your diligence review team must be confident that there will be no impediments to commercializing the IP that is being gained as part of the deal.
Every stone must be turned during a diligence review. As such, when conducting the review, your team must be able to make an informed decision regarding how the IP at issue will increase the company’s overall value, whether by expanding a product line or opening the door to emergence in a new market.
MEET THE INDUSTRY LEADERS AS YOU ENHANCE YOUR DILIGENCE IQ
A multi-faceted process that requires input from a multi-disciplinary team of patent and IP counsel and business executives, the IP due diligence review is a critical component of any deal negotiation that cannot be taken lightly. Due to of the extremely high stakes nature and inherent complexities of the review process, when years and sometimes decades worth of scientific and technical information is involved, it is critical to know not only what you’re looking for but also what the most efficient means are for finding the right information.
LEARN HOW TO ADJUST YOUR IP DUE DILIGENCE PROTOCOL IN LIGHT OF PENDING PATENT REFORM AND FOLLOW-ON BIOLOGICS LEGISLATION
As companies consider the impact of developing caselaw affecting IP in the life sciences industries, as well as proposed follow-on biologic and patent reform legislation, now is the time to consider how emerging changes in the patent and regulatory landscape could modify the manner in which IP transactions are handled within your industry. In this time of economic and business challenges, it is critical that you are aware of how these changes will affect your current IP due diligence practices.
OBTAIN VALUABLE CHECKLISTS AND OTHER WRITTEN MATERIALS THAT WILL SERVE AS A VALUABLE REFERENCE FOR AUDITING YOUR OWN IP DUE DILIGENCE PROCEDURES
Don’t miss this opportunity to learn directly from experienced IP and patent practitioners in the pharmaceutical, biotechnology and medical device industries while benchmarking your current practices against those of the leading companies in your industry. Register now by calling 888-224-2480, faxing your registration to 877-927-1563, or registering online at www.americanconference.com/diligence.
Conference Details
